Business
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW
About this update from Pavmed Inc.
[{"type":"text","content":"Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center\nNEW YORK, Oct. 10, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. (\"Veris\"), today announced that Veris has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities (NIMHD), an institute of the National Institutes of Health (NIH). The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients, in partnership with an academic cancer center. The research project, \"Bridging the Gap: Enhancing Cancer Care for Underserved Populations with the Veris Health Cancer Care Platform,\" will focus on patients facing language barriers, limited access to technology, and socioeconomic disparities.\n\n \n \n \n \n \n \n\n \n\"We are honored to receive this prestigious NIH grant, which recognizes the potential of our Veris Cancer Care Platform to enhance cancer care,\" said James D. Mitchell M.D., PAVmed's Vice President of Digital Health and Veris's Chief Medical Officer. \"This grant will accelerate our efforts to expand the reach and impact of our technology, while strengthening our relationships with academic cancer centers and within the oncology community. We look forward to bringing the benefits of this technology to broader and more diverse patient populations, to improve patient outcomes, reduce healthcare costs, and increase patient access to enhanced cancer care.\"\n\"This NIH grant, which provides Veris with important non-dilutive funding, comes at a pivotal time for Veris, as it pursues financing to advance its commercial strategy, including regulatory clearance and launch of its implantable physiological monitor,\" said Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer. \"This aligns with PAVmed's long-term strategy, which seeks to assure that its subsidiaries, such as Veris, are independently financeable but able to leverage PAVmed's shared infrastructure.\"\nAbout Veris Health\nVeris Health Inc. is a dig...